DXM interaction review
Physiological Hazards of Combining Dextromethorphan with Other Substances
Physiological Hazards of Combining Dextromethorphan with Other Substances
A critical narrative review for education and harm reduction
Physiological Hazards of Combining Dextromethorphan with Other Substances
Literature review date: 2 October 2026
Abstract
Abstract
The strongest grounds for concern about dextromethorphan (DXM) interactions involve monoamine oxidase inhibitors (MAOIs), strongly serotonergic substances, and agents that substantially alter DXM metabolism. With depressants, impaired consciousness, aspiration, and respiratory failure are especially relevant. With stimulants, hyperthermia and cardiovascular stress are central concerns. Interactions with classic psychedelics are less well studied and should not automatically be equated with interactions involving MDMA or MAOIs.
Abstract
This review uses a provisional Physiological Hazard Index (PHI) to organize the evidence. Its ranges express a qualitative hazard judgment. Clinical validation remains outstanding; the scale cannot calculate hospitalization or death probabilities or a safe dose. Mechanisms, evidence quality and possible consequences take precedence over the numerical ratings.
Overview table
Overview table
All rows refer to combinations with DXM. Sort order: descending lower PHI bound, descending upper bound, then alphabetical substance name. When ranges overlap, the comparative hazard order remains uncertain. M / D indicate confidence in the mechanism / the located direct human DXM evidence; H / M / L mean High / Medium / Low. * identifies PK or metabolic-probe evidence, † overdose evidence, and ↓ a negative finding for the specified endpoint and studied conditions. M / D describe confidence in the mechanism and direct evidence for the studied conditions. See the mechanism key in Section 2 and details in Sections 5–8.
Overview table · Substance or group / PHI / M / D / Mechanisms
PHI color scale
- 0
- 1–2
- 3–4
- 5–6
- 7–8
- 9
- 10
Color shows position on the PHI 0–10 scale. Exact numbers and range endpoints are given alongside it. Unrated combinations have their own status.
| Substance or group | PHI | M / D | Mechanisms |
|---|---|---|---|
| Phenelzine, tranylcypromine, isocarboxazid | 9 | H / M | MAO |
| Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changa | 8–9 | H / L | MAO |
| Intravenous methylene blue | 8–9 | H / L | MAO |
| MDMA | 8–9 | H / H* | REL / 2D6 / SYM |
| Moclobemide | 8–9 | H / M*† | MAO / 2D6 |
| Other reversible MAO-A inhibitors | 8–9 | H / L | MAO |
| Selegiline or rasagiline when MAO-B selectivity is lost | 8–9 | H / L | MAO |
| MDA, serotonergic cathinones, and other serotonergic releasers | 7–9 | M / L | REL / SYM |
| Pethidine (meperidine) | 7–9 | H / L | OP / SERT / SEIZ |
| Tramadol | 7–9 | H / M | OP / SERT / SEIZ |
| Fluoxetine, paroxetine | 7–8 | H / M | SERT / 2D6 |
| Methadone | 7–8 | H / M | OP / SERT / 2D6 / CARD |
| Barbiturates, including phenobarbital and pentobarbital | 6–8 | H / L | SED |
| Clomipramine and other tricyclic antidepressants (TCAs) | 6–8 | H / L | SERT / AM / CARD |
| Cocaine | 6–8 | H / L | SYM / SERT |
| Duloxetine | 6–8 | H / L | SERT / 2D6 / SYM |
| Fentanyl | 6–8 | H / L | OP / SED / 5HT-R? |
| GHB, GBL, 1,4-butanediol | 6–8 | H / L | SED |
| Linezolid | 6–8 | H / M↓ | MAO |
| Methamphetamine | 6–8 | M / L | SYM / REL |
| NBOMe compounds, including 25I, 25B, 25C | 6–8 | M / L | 5HT-R / SYM / SEIZ |
| Quinidine | 6–8 | H / H* | 2D6 / CARD |
| Chlorphenamine (chlorpheniramine) | 6–7 | H / M† | SERT / AM / SED |
| Sertraline, escitalopram, citalopram, fluvoxamine | 6–7 | H / M | SERT |
| Venlafaxine, desvenlafaxine | 6–7 | H / L | SERT / SYM |
| Amanita muscaria or Amanita pantherina | 5–7 | M / L | SED |
| Amphetamine, dextroamphetamine | 5–7 | M / L | SYM / REL? |
| Bupropion | 5–7 | H / H* | 2D6 / SEIZ |
| Morphine, hydromorphone, oxycodone, heroin | 5–7 | H / L | OP / SED |
| Nefazodone | 5–7 | M / L | SERT / 5HT-R / 3A |
| PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds | 5–7 | M / L | NMDA / SYM |
| Tapentadol | 5–7 | H / L | OP / SERT / SYM |
| MXE and other ketamine analogues | 4–7 | M / L | NMDA / MONO? |
| 5-MeO-DMT without MAOIs | 4–6 | M / L | 5HT-R / SED |
| Buprenorphine | 4–6 | M / L | OP / SED |
| Codeine | 4–6 | M / L | OP / SED / 2D6 |
| Diphenhydramine, dimenhydrinate, doxylamine | 4–6 | H / L | AM / SED / 2D6? |
| DOx compounds, including DOM, DOB, DOC | 4–6 | M / L | 5HT-R / SYM |
| Ethanol | 4–6 | H / L | SED |
| Ketamine | 4–6 | H / L | NMDA / SED / SYM |
| Methylphenidate | 4–6 | M / L | SYM |
| Muscimol | 4–6 | M / L | SED |
| Oral terbinafine | 4–6 | H / H* | 2D6 |
| Phenibut, baclofen | 4–6 | M / L | SED |
| Pregabalin, gabapentin | 4–6 | H / L | SED |
| Scopolamine with known active-substance exposure | 4–6 | H / L | AM / SED |
| Trazodone | 4–6 | M / L | SERT / 5HT-R / SED |
| Yohimbine | 4–6 | H / L | SYM |
| Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin | 3–6 | M / L | 3A |
| Ritonavir, alone or in ritonavir-boosted regimens | 3–6 | H / M* | 3A / 2D6 |
| Benzodiazepines, including alprazolam, diazepam, clonazepam | 3–5 | H / L | SED |
| Cyclizine, meclizine, hydroxyzine | 3–5 | M / L | AM / SED |
| Kratom (Mitragyna speciosa) | 3–5 | M / M*↓ | OP? / SED / 3A? |
| Memantine | 3–5 | H / L | NMDA |
| Nitrous oxide | 3–5 | H / L | NMDA / HYPOX / B12 |
| Promethazine | 3–5 | H / M* | AM / SED |
| Pseudoephedrine, phenylephrine | 3–5 | M / L | SYM |
| Zolpidem, zopiclone, and other Z-drugs | 3–5 | M / L | SED |
| 2C-B | 2–4 | M / L | 5HT-R / SYM |
| DMT without MAOIs | 2–4 | M / L | 5HT-R / SYM |
| Grapefruit and Seville orange juice | 2–4 | H / M* | 3A |
| Mescaline | 2–4 | M / L | 5HT-R / SYM |
| THC-dominant cannabis | 2–4 | M / L | CB / SYM / IMP |
| Caffeine | 1–3 | M / L | SYM |
| CBD-dominant products | 1–3 | M / M*↓ | CYP / CB |
| Loratadine, desloratadine, cetirizine | 1–3 | M / L | SED? |
| LSD, psilocybin, psilocin | 1–3 | M / L | 5HT-R |
| Nicotine | 1–3 | M / L | SYM |
| Salvinorin A (Salvia divinorum) | 1–3 | M / L | KOR / IMP |
| Fexofenadine | 1–2 | M / L | None identified |
Overview table
Outside numerical ranking:
Overview table · Product / Scope note
| Product | Scope note |
|---|---|
| Combination medicines containing acetaminophen (paracetamol) | Not assessed as a two-substance recreational combination; see Section 11 |
1. Scope and assumptions
1. Scope and assumptions
The assessment primarily concerns acute interactions between two substances in an adult familiar with each substance individually, without allergy or unusual sensitivity, at exposures regarded as ordinary recreational use. Psychological stability and substantial experience are assumed. Panic, unpleasant experiences, and the intensity of psychedelic effects receive relatively little weight on their own.
1. Scope and assumptions
Additional assumptions are the absence of significant cardiac, hepatic, renal, or respiratory disease, epilepsy, pregnancy, withdrawal, and a third interacting substance. These conditions define the assessment’s scope. Substance identity and composition are assumed to be known; substitution and contamination are outside the assessment. Mushrooms and plant preparations have inherently variable composition, which is discussed separately.
1. Scope and assumptions
The main outcomes considered are serotonin toxicity, seizures, hyperthermia, arrhythmias, severe hypertension, respiratory failure, and organ injury. Aspiration and hypoxia are also included. A blackout without physical consequences receives less weight than unconsciousness accompanied by impaired breathing. Falls and other injuries are secondary hazards and are distinguished from direct molecular toxicity.
1. Scope and assumptions
Assessment depends on the amount taken, blood concentration, route of administration, timing and overlap of effects. The phrase “ordinary recreational dose” describes those conditions too vaguely to predict an individual outcome. Inhibition of metabolism can turn a familiar amount of a substance into an unfamiliar systemic exposure.
2. Sources and methods
2. Sources and methods
This review reassesses the interaction claims in William E. White’s The Dextromethorphan FAQ, Text Version 4.0 (1997), particularly Section 13 [1], against human studies, prescribing information, clinical reports, and scientific reviews. Targeted searches of accessible scientific and regulatory sources were conducted on 2 October 2026. Topics included CYP2D6, MDMA, serotonin toxicity, opioids, cannabinoids, MAOIs, antihistamines, and other dissociatives.
2. Sources and methods
This is a critical narrative review. Study selection and discussion proceeded without a registered protocol or independent duplicate selection; the work includes no pooled risk calculation. Some publications were available only as abstracts. The conclusions are limited to the material read.
2. Sources and methods
Two confidence dimensions accompany the ratings:
M: confidence in the relevant mechanism.
D: confidence in the located direct human evidence involving DXM, for the endpoint and conditions actually studied. Read D together with the description of what was measured and at which exposures.
2. Sources and methods
H / M / L denote High / Medium / Low confidence. Evidence flags specify endpoint, direction, and scope:
*: pharmacokinetic or metabolic-phenotyping evidence.
†: clinical evidence comes from overdose and concerns those exposures.
↓: the specified adverse or metabolic endpoint was not observed under the studied conditions.
2. Sources and methods
Flags may be combined. High D for a metabolic ratio concerns that measured ratio. DXM AUC is a distinct measure of concentration over time. General statements such as “extrapolation” apply to all Low-D rows unless a specific direct finding is identified; repeated absence-of-data warnings are omitted where the legend already explains them.
2. Sources and methods
The FAQ’s descriptions of subjective effects are treated as user reports. Reddit or Erowid anecdotes cannot reliably establish exposure counts, composition or complication rates, so those anecdotes are excluded from numerical calibration. Pharmacological extrapolation is identified where direct evidence is limited.
Mechanism key
Mechanism key
Tags identify the principal pathways discussed for a specific combination. The hazard rating concerns the whole pair under its stated conditions. A question mark identifies a variable or uncertain contribution.
Mechanism key · Tag / Meaning
| Tag | Meaning |
|---|---|
| MAO | Monoamine oxidase inhibition; MAO-A activity is particularly relevant to serotonin toxicity |
| SERT | Serotonin reuptake inhibition |
| REL | Monoamine release, with serotonergic contribution where indicated |
| 5HT-R | Serotonin receptor effects; does not mean the same mechanism as release or SERT inhibition |
| 2D6 / 3A / CYP | Modification of CYP2D6 / CYP3A / multiple CYP metabolic pathways; not a fixed exposure multiplier |
| SED | Additive sedation, impaired consciousness or protective reflexes, and possible respiratory consequences |
| OP | μ-opioid effects and associated respiratory hazards |
| SYM | Sympathetic or autonomic cardiovascular/thermal stress |
| AM | Antimuscarinic effects, including impaired sweating and peripheral toxicity |
| CARD | Additional cardiac electrophysiological effects, including QT-related concerns where specified |
| SEIZ | An additional seizure-related concern |
| NMDA | Overlapping NMDA-antagonist effects |
| HYPOX / B12 | Oxygen deprivation / functional vitamin B12 inactivation, principally intrinsic N2O hazards |
| KOR | κ-opioid receptor effects; distinct from conventional μ-opioid respiratory effects |
| CB / IMP | Cannabinoid-related effects / functional impairment and secondary physical hazards |
| MONO | Variable additional monoamine effects within a heterogeneous group |
Mechanism key
These pathways do not exhaust the pharmacology of every substance. The detailed notes distinguish direct findings, the second substance’s own toxicity, and inferred interactions.
3. The index and its limitations
3. The index and its limitations
PHI is an ordinal aid to comparison. A larger number indicates greater physiological concern; it does not specify the probability that treatment, hospitalization, or death will occur. Contraindications, isolated poisonings, and plausible mechanisms cannot establish an almost inevitable outcome without defined exposures and an observed outcome rate in a comparable population.
3. The index and its limitations · PHI / Interpretation in this review
| PHI | Interpretation in this review |
|---|---|
| 0 | Demonstrated absence of a substantial additional hazard under specified conditions; not assigned to any combination |
| 1–2 | Small expected additional physiological hazard; evidence of safety may still be absent |
| 3–4 | Meaningful amplification of adverse effects or functional impairment; serious consequences are possible under unfavorable conditions |
| 5–6 | Substantial interaction with a plausible risk of a clinically significant complication |
| 7–8 | High concern because of multiple mechanisms or the potential for severe poisoning |
| 9 | Highest concern and strong grounds to avoid the combination, including contraindications or a closely relevant mechanism of severe toxicity |
| 10 | Reserved for evidence of an almost inevitable catastrophic outcome under defined conditions; not assigned |
3. The index and its limitations
Ranges reflect heterogeneous conditions and uncertainty in the assessment. They are not confidence intervals. Adjacent scores express a qualitative difference in judgments. They cannot be used to calculate a risk ratio. The index considers the physiological hazards of the whole combination while identifying the contribution of the interaction. The second substance’s own toxicity and its interaction with DXM are described as different components of hazard.
3. The index and its limitations
Confidence in the exact numerical boundaries of all ratings is Low; mechanism confidence cannot validate an ordinal score.
3. The index and its limitations
The operational rule for PHI 8–9 is highest concern when a potentially severe toxic mechanism is supported by a contraindication, or when several substantial pathways of toxicity coincide. With Low D at this level, the rating rests principally on mechanisms. This applies to reversible MAO-A inhibitors, harmala-containing preparations, and loss of MAO-B selectivity.
3. The index and its limitations
Wider ranges have specific sources of uncertainty. For MXE and ketamine analogues (4–7), these include differences between molecules, additional targets, and duration. For MDA and serotonergic releasers (7–9), they include group heterogeneity, route, exposure, and overlap of effects. For tramadol (7–9), exposure and the CYP2D6-dependent balance between parent drug and active metabolite are relevant. For pethidine (7–9), exposure and metabolite contribution, particularly with repeated use, matter. These factors explain the width of the qualitative ranges. Unknown identity or contamination is not assumed.
3. The index and its limitations
Interpretation should proceed from the specific mechanism and severity of possible consequences, to evidence quality, and finally to the index. Reliable ranking is generally not possible when ranges overlap.
4. Pharmacological basis
4. Pharmacological basis
DXM and its active metabolite dextrorphan (DXO) have different pharmacological profiles. NMDA receptor blockade, DXM’s effects on the serotonin transporter (SERT), and CYP2D6 metabolism are particularly relevant. In Rickli’s human-transporter assay, DXM inhibited SERT as potently as fluoxetine. The result shows the relevance of SERT to serotonin-toxicity mechanisms under the conditions of that transporter assay [5]. CYP2D6 converts DXM to DXO; CYP3A contributes to another metabolic pathway. CYP2D6 inhibition can substantially increase exposure to parent DXM and alter the DXM-to-DXO balance [2, 4, 19].
4. Pharmacological basis
DXM has dissociative effects and a pharmacological profile that differs from conventional μ-opioid agonists. Respiratory impairment can occur in severe DXM poisoning; its magnitude for DXM, morphine and fentanyl should be assessed in light of the differences among the substances. Combined sedation can impair protective reflexes and increase the consequences of vomiting.
4. Pharmacological basis
For serotonin toxicity, an especially important pattern is increased serotonin release or reduced reuptake together with inhibition of serotonin breakdown through MAO. Many psychedelics act through 5-HT2A agonism, while MDMA increases serotonin release. Interaction concerns depend on each substance’s specific mechanism [8, 9].
4. Pharmacological basis
Psychological resilience does not prevent enzyme inhibition, hyperthermia, seizures, arrhythmias, or aspiration. Experience can change how tolerable an altered state feels; the listed physiological mechanisms remain.
5. Serotonergic substances and stimulants
5. Serotonergic substances and stimulants
Every row describes a combination with DXM. References support mechanisms and reported clinical signals. PHI numbers are provisional judgments in the review. Rows without a reference are provisional pharmacological extrapolations.
5. Serotonergic substances and stimulants · Substance or group / PHI / M / D / Mechanisms / Main physiological concern and evidence
| Substance or group | PHI | M / D | Mechanisms | Main physiological concern and evidence |
|---|---|---|---|---|
| Phenelzine, tranylcypromine, isocarboxazid | 9 | H / M | MAO | MAO inhibition combined with SERT effects; severe serotonin toxicity; contraindication; historical possible fatal reaction involving phenelzine [2, 4, 42] |
| Moclobemide | 8–9 | H / M*† | MAO / 2D6 | MAO-A inhibition plus direct human inhibition of DXM O-demethylation; fatal overdose reported [27, 43] |
| Other reversible MAO-A inhibitors | 8–9 | H / L | MAO | Reversible MAO-A inhibitors retain the class mechanism of severe toxicity [2, 9]. |
| Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changa | 8–9 | H / L | MAO | The concern rests on MAO-A inhibition by harmala components. The directory has a dedicated entry for DMT without MAOIs [9]. |
| Selegiline or rasagiline when MAO-B selectivity is lost | 8–9 | H / L | MAO | MAO-A inhibition becomes relevant when selectivity is lost. This depends on the conditions of selegiline or rasagiline use [26, 34]. |
| Linezolid | 6–8 | H / M↓ | MAO | Mild reversible MAO inhibition; negative controlled DXM interaction findings at therapeutic exposure. Concern at other exposures is mechanistic; AUVELITY contraindicates coadministration [2, 39, 40] |
| Intravenous methylene blue | 8–9 | H / L | MAO | The high rating rests on potent MAO-A inhibition and the AUVELITY contraindication [2, 41]. |
| Fluoxetine, paroxetine | 7–8 | H / M | SERT / 2D6 | Serotonergic effects plus strong CYP2D6 inhibition; increased DXM exposure [2, 4] |
| Sertraline, escitalopram, citalopram, fluvoxamine | 6–7 | H / M | SERT | Serotonin toxicity; CYP contribution varies between drugs [2, 6, 7] |
| Duloxetine | 6–8 | H / L | SERT / 2D6 / SYM | SNRI effects plus CYP2D6 inhibition; limited quantitative assessment of the pair [2] |
| Venlafaxine, desvenlafaxine | 6–7 | H / L | SERT / SYM | SERT effects and noradrenergic stress; limited direct evidence [2] |
| Clomipramine and other tricyclic antidepressants (TCAs) | 6–8 | H / L | SERT / AM / CARD | Heterogeneous class; serotonergic, anticholinergic, and cardiac effects [2, 4] |
| Trazodone | 4–6 | M / L | SERT / 5HT-R / SED | Serotonergic effects and sedation; pair-specific risk not measured |
| Nefazodone | 5–7 | M / L | SERT / 5HT-R / 3A | Serotonergic effects and CYP3A inhibition. Hepatotoxicity is described for nefazodone itself. |
| MDMA | 8–9 | H / H* | REL / 2D6 / SYM | Serotonergic and autonomic stress; marked alteration of DXM PK; *High D concerns PK [3] |
| MDA, serotonergic cathinones, and other serotonergic releasers | 7–9 | M / L | REL / SYM | Class extrapolation; MDMA’s CYP2D6 effect cannot automatically be transferred to other substances |
| Amphetamine, dextroamphetamine | 5–7 | M / L | SYM / REL? | Blood pressure, heart rate, temperature; possible serotonergic contribution |
| Methamphetamine | 6–8 | M / L | SYM / REL | Autonomic and serotonergic stress; severity of the pair not calibrated |
| Cocaine | 6–8 | H / L | SYM / SERT | Sympathetic stress, ischemia, arrhythmias, and SERT effects |
| Methylphenidate | 4–6 | M / L | SYM | Predominantly catecholaminergic effects. |
| Yohimbine | 4–6 | H / L | SYM | The rating is based on adrenergic stress. The Olney’s lesions hypothesis is part of the historical FAQ discussion [1, 21]. |
| Pseudoephedrine, phenylephrine | 3–5 | M / L | SYM | Additional cardiovascular stress; no separate quantitative study identified |
| Caffeine | 1–3 | M / L | SYM | Heart rate and blood pressure; not equated with potent stimulants |
| Nicotine | 1–3 | M / L | SYM | Heart rate, blood pressure and nausea. The FAQ includes reports of strong potentiation of DXM’s effects [1]. |
MAOIs and MDMA
MAOIs and MDMA
MAOIs occupy the highest concern category because of mechanisms and contraindications. A 1970 primary report describes an individual case of a possible lethal reaction involving phenelzine (Nardil) and DXM [42]. Harmalas remain MAO-A inhibitors regardless of plant origin. Ayahuasca and harmala-containing changa do not belong in the DMT-without-MAOI category.
MAOIs and MDMA
Selegiline and rasagiline selectivity depends on the conditions of use, which matter to the combination’s assessment. The rasagiline contraindication with DXM includes concern about psychosis or unusual behavior. With physiological toxicity as the main outcome, this does not justify automatically equating selective MAO-B inhibition with nonselective MAO inhibition. Evidence is insufficient for a numerical physiological ranking when selectivity is maintained. When selectivity is lost, the MAO-A mechanism applies. ZELAPAR, a selegiline formulation, also contraindicates DXM. XADAGO (safinamide), another MAO-B inhibitor, contraindicates DXM and explicitly cites psychosis or abnormal behavior reported with MAOI–DXM combinations. These warnings remain relevant, but their psychiatric rationale does not independently calibrate physiological toxicity under maintained MAO-B selectivity [26, 34, 44].
MAOIs and MDMA
A pilot study in four extensive metabolizers found that moclobemide markedly reduced DXM O-demethylation without affecting DXO N-demethylation. The study provides direct human data on DXM metabolism under MAO-A inhibition [43]. Harada and colleagues reported a fatal DXM–moclobemide overdose in 2025. Serotonin syndrome was inferred from autopsy and toxicological findings. This is a direct human signal of potentially severe toxicity, but one postmortem case cannot determine outcome probability at recreational exposures. Unreported circumstances cannot be reconstructed by assumption [27].
MAOIs and MDMA
A controlled study involved 15 healthy men. They took MDMA by mouth, followed by DXM as a metabolic probe. DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3]. The abstract reports CYP2D6 recovery after approximately 10 days, with a recovery half-life of 46.6 hours. In the full text, this half-life is estimated by fitting a monoexponential model to a urinary metabolic-ratio marker. The Results and Discussion describe a remaining departure of that marker from baseline at the 10-day observation and limitations of the recovery models. [3] These findings describe pharmacokinetics and enzyme-probe measurements. The fold change can differ at other doses because of metabolic saturation and exposure-dependent inhibition. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval. The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].
MAOIs and MDMA
The PHI 8–9 judgment rests on the combination of serotonin release, increased DXM exposure and autonomic/hyperthermic stress. This mechanistic basis differs from the contraindications and clinical signals for traditional MAOIs.
MAOIs and MDMA
Targeted searching did not identify separate clinical reports with adequately described outcomes specifically for the MDMA–DXM pair. The search had limited coverage.
Linezolid and intravenous methylene blue
Linezolid and intravenous methylene blue
Linezolid mildly and reversibly inhibits MAO. Methylene blue differs through potent MAO-A inhibition [39, 41]. Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations. Current linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40]. These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Linezolid and intravenous methylene blue
AUVELITY labeling specifically contraindicates initiation with linezolid or intravenous methylene blue [2]. That warning concerns the DXM–bupropion product. For linezolid with DXM, PHI 6–8 is a provisional mechanistic assessment incorporating the negative trial. Intravenous methylene blue remains at 8–9 because of potent MAO-A inhibition and the contraindication; direct DXM-specific clinical outcome evidence is limited [2, 41].
Antidepressants and clinical reports
Antidepressants and clinical reports
Fluoxetine and paroxetine are distinguished from other selective serotonin reuptake inhibitors (SSRIs) because serotonergic effects coincide with strong CYP2D6 inhibition. TCAs vary in SERT inhibition, anticholinergic activity and cardiac effects. Nefazodone and trazodone have pharmacological profiles that differ from SSRIs [2].
Antidepressants and clinical reports
Clinical reports describe serotonin toxicity involving DXM and SSRIs. The frequency of these outcomes remains unknown. In a 2025 report, a patient taking sertraline received Bromfed DM, containing DXM, brompheniramine and pseudoephedrine. The full text describes the prescribed regimen; symptoms developed approximately three days after treatment began. The authors interpret the case as toxicity during therapeutic use. Information about the amount taken comes from the case description; the involvement of several ingredients leaves the contribution of the pure DXM–sertraline pair uncertain [7].
6. Opioids and other depressants
6. Opioids and other depressants · Substance or group / PHI / M / D / Mechanisms / Main physiological concern and evidence
| Substance or group | PHI | M / D | Mechanisms | Main physiological concern and evidence |
|---|---|---|---|---|
| Tramadol | 7–9 | H / M | OP / SERT / SEIZ | Serotonergic effects [5]; seizures and opioid effects [51]; multiple pathways of toxicity |
| Pethidine (meperidine) | 7–9 | H / L | OP / SERT / SEIZ | SERT inhibition [5]; respiratory depression and seizure potential of its metabolite, with accumulation during prolonged use [52] |
| Methadone | 7–8 | H / M | OP / SERT / 2D6 / CARD | Serotonergic effects [5], respiration [53], and duration (endpoint unspecified in this review); CYP2D6 inhibition shown in humans [20] |
| Fentanyl | 6–8 | H / L | OP / SED / 5HT-R? | Primarily its own respiratory depression; a separate serotonergic signal [5] |
| Tapentadol | 5–7 | H / L | OP / SERT / SYM | Opioid effects plus demonstrated SERT/NET inhibition; the clinical contribution of the DXM interaction remains uncertain [5] |
| Morphine, hydromorphone, oxycodone, heroin | 5–7 | H / L | OP / SED | The main concerns involve breathing, consciousness and material entering the airways. These opioids differ from tramadol in their effects on serotonin reuptake [5]. |
| Codeine | 4–6 | M / L | OP / SED / 2D6 | Opioid effects; variable CYP2D6-mediated conversion of codeine to morphine [54, 55] |
| Buprenorphine | 4–6 | M / L | OP / SED | Opioid sedation — drowsiness and reduced alertness. Concerns about the DXM combination remain even when individual effects reach a ceiling [5]. |
| Kratom (Mitragyna speciosa) | 3–5 | M / M*↓ | OP? / SED / 3A? | *A single low exposure did not alter DXM PK; sedation and other exposure conditions remain separate issues [29] |
| Ethanol | 4–6 | H / L | SED | Sedation, vomiting, aspiration; neuroprotection not established [1] |
| Benzodiazepines, including alprazolam, diazepam, clonazepam | 3–5 | H / L | SED | Consciousness, coordination, protective reflexes; not all consequences are direct respiratory depression [1] |
| Zolpidem, zopiclone, and other Z-drugs | 3–5 | M / L | SED | Sedation and impaired consciousness; pharmacodynamic extrapolation |
| Barbiturates, including phenobarbital and pentobarbital | 6–8 | H / L | SED | Marked CNS and respiratory depression; pair-specific complication rate unknown [1] |
| GHB, GBL, 1,4-butanediol | 6–8 | H / L | SED | Coma and respiratory failure; steep concentration–effect relationship for GHB [11] |
| Pregabalin, gabapentin | 4–6 | H / L | SED | Sedation, ataxia; respiratory concern increases with additional risk factors [12] |
| Phenibut, baclofen | 4–6 | M / L | SED | GABA-B effects and sedation; direct DXM interaction insufficiently studied |
| Muscimol | 4–6 | M / L | SED | GABA-A effects, impaired consciousness, aspiration [16] |
| Amanita muscaria or Amanita pantherina | 5–7 | M / L | SED | Muscimol, ibotenic acid and variable composition. The source describes mushroom properties and toxicity; information on the DXM combination is limited [16]. |
6. Opioids and other depressants
The oral tramadol prescribing information describes respiratory depression and increased seizure risk [51]. The oral meperidine prescribing information describes respiratory depression and seizures associated with metabolite accumulation during prolonged use [52]. The methadone prescribing information describes respiratory depression [53]. These warnings concern the opioids' own pharmacology. The endpoint meant by duration in the methadone row remains unspecified.
6. Opioids and other depressants
CYP2D6 converts codeine to morphine; morphine formation varies with CYP2D6 phenotype [54, 55]. The codeine label describes reduced morphine concentrations during CYP2D6 inhibition and warns of respiratory depression and sedation with other CNS depressants [54]. These sources concern codeine pharmacology. The clinical magnitude of its interaction with DXM remains uncertain.
Why opioids are separated
Why opioids are separated
Experiments with human transporters show substantial differences between opioids. Tramadol, pethidine, and methadone have serotonergic mechanisms, whereas morphine and hydromorphone did not demonstrate analogous SERT inhibition in the studied system. Fentanyl has a separate clinical serotonergic signal without the same transporter inhibition. Tapentadol inhibited SERT at potentially clinically relevant concentrations and was the most potent NET inhibitor among the tested opioids. The transporter mechanism is well supported; uncertainty concerns the clinical severity of the DXM pair, so its M confidence is High and D remains Low [5].
Why opioids are separated
In Rickli’s study, morphine, heroin, oxycodone, codeine, hydrocodone, hydromorphone, and buprenorphine did not inhibit SERT or the norepinephrine transporter (NET). The result concerns SERT and NET inhibition under that laboratory assay’s conditions; effects in vivo may differ [5].
Why opioids are separated
With nonserotonergic opioids, the principal concerns are breathing and consciousness. The assessment rests on pharmacological mechanisms; the extent of their amplification with DXM remains uncertain. There is no basis for relying on DXM to protect against opioid toxicity.
Kratom
Kratom
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe. Midazolam exposure increased, consistent with an intestinal CYP3A interaction. Under the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Why depressants have different ratings
Why depressants have different ratings
Clinicians use benzodiazepines to treat some toxic states under controlled conditions. Physiological concerns remain when they are independently combined with DXM. Benzodiazepine respiratory hazards differ from those of barbiturates. Other physiological hazards may persist as agitation decreases [1].
Why depressants have different ratings
GHB’s own hazard includes its steep concentration–effect relationship: progression to deep sedation can be abrupt. The combination rating reflects that property and potentially additive impairment of consciousness; direct evidence of a specific DXM–GHB synergy is insufficient [11].
Why depressants have different ratings
The FDA warns about respiratory complications involving gabapentin and pregabalin, particularly with depressants and underlying respiratory risk factors. The warning concerns those drugs and conditions; the outcome probability for a healthy person combining them with DXM remains uncertain from these data [12].
7. Dissociatives and psychedelics
7. Dissociatives and psychedelics · Substance or group / PHI / M / D / Mechanisms / Main physiological concern and evidence
| Substance or group | PHI | M / D | Mechanisms | Main physiological concern and evidence |
|---|---|---|---|---|
| Ketamine | 4–6 | H / L | NMDA / SED / SYM | Additive dissociation, vomiting, impaired protective reflexes, blood pressure; specific synergy not measured [14] |
| PCP, 3-MeO-PCP, 3-HO-PCP, and related compounds | 5–7 | M / L | NMDA / SYM | Heterogeneous NMDA and additional effects; autonomic stress and prolonged impairment |
| MXE and other ketamine analogues | 4–7 | M / L | NMDA / MONO? | Heterogeneous group; additional monoamine effects possible for some compounds |
| Memantine | 3–5 | H / L | NMDA | Overlapping NMDA effects and long duration; labeling notes lack of systematic assessment of the pair [14] |
| Nitrous oxide | 3–5 | H / L | NMDA / HYPOX / B12 | Dissociation plus its own hypoxia hazards; repeated use introduces a separate B12-related hazard [13] |
| LSD, psilocybin, psilocin | 1–3 | M / L | 5HT-R | Direct organ toxicity of the interaction not established; vomiting and autonomic effects possible [1, 8] |
| Mescaline | 2–4 | M / L | 5HT-R / SYM | More prominent nausea and autonomic stress; not the MDMA mechanism [8] |
| DMT without MAOIs | 2–4 | M / L | 5HT-R / SYM | Acute autonomic effects and impairment; little direct DXM evidence [8] |
| 5-MeO-DMT without MAOIs | 4–6 | M / L | 5HT-R / SED | Impaired consciousness and possible serotonergic contribution; principally extrapolative rating [9] |
| 2C-B | 2–4 | M / L | 5HT-R / SYM | Receptor-mediated psychedelic with autonomic effects; MDMA PK findings cannot be transferred [1] |
| DOx compounds, including DOM, DOB, DOC | 4–6 | M / L | 5HT-R / SYM | Prolonged autonomic and vascular stress; pair-specific risk not established |
| NBOMe compounds, including 25I, 25B, 25C | 6–8 | M / L | 5HT-R / SYM / SEIZ | Their own systemic toxicity, seizures, hyperthermia; additional DXM hazard inferred [15] |
| Salvinorin A (Salvia divinorum) | 1–3 | M / L | KOR / IMP | Specific toxic synergy not established; functional impairment and secondary physical hazards [17] |
| THC-dominant cannabis | 2–4 | M / L | CB / SYM / IMP | Heart rate, vomiting, coordination; much of the potentiation is subjective [1, 10] |
| CBD-dominant products | 1–3 | M / M*↓ | CYP / CB | *Direct PK evidence limited to a specific study; marked CYP2D6 inhibition not found [10] |
Dissociatives
Dissociatives
Dissociative interactions depend on NMDA blockade kinetics, concentrations and additional targets. These differences remain relevant when substances share a binding site. The FAQ used the proximity of ketamine and DXM binding sites to explain a small additional effect; that explanation is insufficient to assess the interaction. Memantine labeling describes its combination with DXM as insufficiently studied systematically [1, 14].
Dissociatives
PCP, MXE and research analogues differ in their properties. They are grouped for an overview; with Low D, the comparative position of individual molecules remains uncertain. Long-term interaction outcomes are also unknown.
Dissociatives
For nitrous oxide, hypoxia depends partly on inhalation conditions and oxygen availability. Functional B12 inactivation is an intrinsic N2O hazard, particularly with repeated use or susceptibility. There is no evidence here that DXM directly amplifies that biochemical pathway. The FAQ’s claim of potentiation without additional adverse effects is not substantiated [1, 13].
Psychedelics and cannabinoids
Psychedelics and cannabinoids
With psychological effects given relatively little weight, LSD and psilocybin rank below MDMA and MAOIs. These groups differ in the serotonin-elevating mechanisms underlying the assessment [8].
Psychedelics and cannabinoids
5-MeO-DMT differs in pharmacology and reports of severe toxicity in other combinations. Direct DXM evidence is extremely limited, so the PHI 4–6 range remains unstable. Combinations containing harmalas use the MAOI category [9].
Psychedelics and cannabinoids
Controlled studies of salvinorin A alone found relatively stable physiological measures under the studied conditions; they did not examine DXM. Salvinorin acts through a κ-opioid mechanism. Its pharmacology differs from the μ-opioid mechanism of fentanyl’s respiratory effects [17].
Psychedelics and cannabinoids
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6. This contradicts a categorical claim that CBD must markedly increase DXM exposure specifically through CYP2D6. The CBD-rich product also contained THC and increased THC AUC by 161% relative to the THC-only product, consistent with inhibition of oral THC clearance. A CBD-dominant product is therefore not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
8. Antihistamines and modifiers of metabolism
8. Antihistamines and modifiers of metabolism · Substance or group / PHI / M / D / Mechanisms / Main physiological concern and evidence
| Substance or group | PHI | M / D | Mechanisms | Main physiological concern and evidence |
|---|---|---|---|---|
| Chlorphenamine (chlorpheniramine) | 6–7 | H / M† | SERT / AM / SED | SERT and anticholinergic effects; poisonings involving combination products [6] |
| Diphenhydramine, dimenhydrinate, doxylamine | 4–6 | H / L | AM / SED / 2D6? | Sedation and anticholinergic effects; CYP2D6 contribution better supported for diphenhydramine [18] |
| Fexofenadine | 1–2 | M / L | None identified | No substantial toxic mechanism of the pair identified; direct proof of safety absent |
| Loratadine, desloratadine, cetirizine | 1–3 | M / L | SED? | Sedation varies across this group; concerns depend on the individual drug. |
| Bupropion | 5–7 | H / H* | 2D6 / SEIZ | *Established increase in DXM exposure; its own seizure hazard [2] |
| Quinidine | 6–8 | H / H* | 2D6 / CARD | *Direct PK evidence; additional QT and arrhythmia concerns depend on conditions [4, 19] |
| Oral terbinafine | 4–6 | H / H* | 2D6 | *Direct metabolic-phenotyping evidence of CYP2D6 inhibition. High confidence H concerns that measured endpoint [23]. |
| Grapefruit and Seville orange juice | 2–4 | H / M* | 3A | *DXM PK changes shown; clinical importance depends on metabolism [22] |
| Ritonavir, alone or in ritonavir-boosted regimens | 3–6 | H / M* | 3A / 2D6 | *Direct human metabolic-probe data differ between regimens and endpoints; not a uniform strong CYP2D6 effect [45, 46] |
| Other strong CYP3A inhibitors, including cobicistat, azoles, clarithromycin | 3–6 | M / L | 3A | Reduced alternative metabolism; heterogeneous effects [24] |
Therapeutic combinations and recreational exposure
Therapeutic combinations and recreational exposure
AUVELITY combines DXM with bupropion; NUEDEXTA combines DXM with quinidine. These products use increased DXM exposure therapeutically with a defined formulation, regimen and patient selection. Evidence about this use applies to those conditions [2, 4].
Therapeutic combinations and recreational exposure
Bupropion’s principal relevant properties are CYP2D6 inhibition and its own dose-dependent seizure hazard. These properties of bupropion itself matter when interpreting AUVELITY’s seizure warnings [2].
Therapeutic combinations and recreational exposure
Quinidine raises and prolongs DXM exposure. Its own cardiac effects matter; the hazards of a therapeutic low-dose formulation and arbitrary quinidine exposure differ. The index does not assign prescribed NUEDEXTA the same hazard as an uncontrolled recreational combination [4, 19].
Therapeutic combinations and recreational exposure
In Capon and colleagues’ study, DXM AUC was approximately 150 times higher in poor CYP2D6 metabolizers than in extensive metabolizers; quinidine increased AUC approximately 43-fold in extensive metabolizers. The first comparison concerns phenotypes, the second an intervention. Each multiplier concerns the stated group and conditions of AUC measurement [28].
Ritonavir and regimen-dependent effects
Antihistamines and citrus juice
Antihistamines and citrus juice
The review of DXM–chlorphenamine poisonings supports chlorphenamine’s contribution to serotonin toxicity. The cases primarily involve overdoses and show a hazardous mechanism; outcome frequency and severity at lower exposures remain uncertain. The review found no chlorphenamine-only case meeting its serotonin-toxicity criteria. In combination, two substances may jointly contribute to toxicity even when reports about each one alone have not identified it [6].
Antihistamines and citrus juice
The 6–7 range under the review’s non-overdose assumptions reflects mechanistic concern. Clinical reports mainly describe overdoses. Outcome severity and frequency at lower exposures remain uncertain; the PHI boundaries are extrapolative judgments.
Antihistamines and citrus juice
Diphenhydramine’s CYP2D6 inhibition is supported by in vitro findings and human interactions involving other substrates; the effect on DXM cannot be calculated from those observations. Other sedating antihistamines need not share the same CYP effect to create hazards [18]. Historical warnings about terfenadine cannot be transferred to all modern nonsedating antihistamines.
Antihistamines and citrus juice
Human studies of grapefruit and Seville orange juice show changes in DXM bioavailability. CYP2D6 does not account for most of those changes. The terbinafine findings concern the DXM-to-DXO metabolic ratio. That measure compares the drug with its metabolite; AUC describes DXM concentration over time [22, 23].
Additional anticholinergic and antiemetic agents
Additional anticholinergic and antiemetic agents · Substance or group / PHI / M / D / Mechanisms / Main physiological concern and evidence
| Substance or group | PHI | M / D | Mechanisms | Main physiological concern and evidence |
|---|---|---|---|---|
| Scopolamine with known active-substance exposure | 4–6 | H / L | AM / SED | Antimuscarinic effects, hyperthermia, impairment, not a DXM trial [32] |
| Promethazine | 3–5 | H / M* | AM / SED | *Therapeutic DXM combination and labeling; sedation, respiratory and anticholinergic concerns [33] |
| Cyclizine, meclizine, hydroxyzine | 3–5 | M / L | AM / SED | Sedative and anticholinergic effects differ, not established severity of each pair |
Additional anticholinergic and antiemetic agents
Sedation and peripheral anticholinergic toxicity should be distinguished. Scopolamine can reduce sweating and contribute to overheating, tachycardia, and urinary retention regardless of the subjective unpleasantness of delirium. Tropane-containing plant preparations are excluded from the numerical matrix: familiarity with the plant does not ensure a stable alkaloid concentration [32, 35].
Additional anticholinergic and antiemetic agents
A prescription product combines promethazine with DXM. Its labeling describes conditions of use, sedation and other hazards. These findings concern the product’s labeled use. For other sedating antiemetics, the assessment extrapolates from class properties; CYP and QT effects vary among drugs [33].
Additional anticholinergic and antiemetic agents
Ondansetron is a 5-HT3 antagonist. Its label warns about serotonin syndrome; the pharmacological interpretation and causality of those reports have been challenged. Its own condition-dependent QT-prolonging hazard is more clearly described. Quantitative evidence for the ondansetron–DXM pair during recreational use is insufficient, so it remains without PHI. The review retains both positions on serotonin syndrome [30, 31].
Additional anticholinergic and antiemetic agents
NUEDEXTA contains DXM and quinidine. Quinidine has its own electrophysiological effects, which account for part of the QT warnings. QT-prolonging drugs differ in pharmacology and concerns, so the review gives this group no shared numerical rating. CYP inhibition and electrolyte disturbances associated with vomiting may matter for an individual pair [4].
9. Exclusions, repeated use, and limits of extrapolation
9. Exclusions, repeated use, and limits of extrapolation
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
9. Exclusions, repeated use, and limits of extrapolation
Repeated use raises concerns beyond acute tolerability. Long-term data are absent for most combinations. Assessment depends on the specific substances and conditions; the review provides no basis for a uniform “neurotoxicity” penalty across dissociatives.
9. Exclusions, repeated use, and limits of extrapolation
Repeated use introduces accumulation of long-acting substances, persistent CYP inhibition, the second substance’s own hazards and withdrawal states. Chronic complications of ketamine and N2O are described for the substances themselves; DXM’s effect on how quickly they develop remains unknown. Delayed complications may emerge after a period of feeling well.
9. Exclusions, repeated use, and limits of extrapolation
The comparison can change with better specification of exposure, route, single versus repeated use, timing, other medications, and organ function. Controlled PK data could reduce uncertainty about exposure; studies of clinical outcomes could alter the ranking. Research chemicals, 5-MeO-DMT, phenibut, and multicomponent plant products have particularly unstable ratings.
9. Exclusions, repeated use, and limits of extrapolation
Piracetam, DMAE, and lecithin are excluded from the numerical matrix. The FAQ contains accounts of subjective memory improvement, but evidence is insufficient to treat them as protection against physical injury.
9. Exclusions, repeated use, and limits of extrapolation
Lithium, St John’s wort, 5-HTP and tryptophan have no PHI in the review because data for a numerical comparison are limited: their pharmacology, product composition and conditions of use differ. Mirtazapine, buspirone, triptans and cyclobenzaprine also differ in mechanisms and physiological hazards. The review gives this list no shared PHI range. ACMT lists triptans and St John’s wort as possible interacting agents; its warning lists substances without numerical estimates for individual pairs [25]. The absence of PHI reflects limited grounds for a comparative number.
9. Exclusions, repeated use, and limits of extrapolation
Interactions involving three or more substances cannot be calculated by adding scores.
9. Exclusions, repeated use, and limits of extrapolation
DXM plus α-PVP is included without a PHI. Evidence covers laboratory transporter tests and poisoning observations; the severity of this specific combination remains uncertain [56, 57, 58].
9. Exclusions, repeated use, and limits of extrapolation
α-PVP (alpha-pyrrolidinovalerophenone) is a stimulant. In cells expressing human monoamine transporters, it inhibited dopamine and norepinephrine uptake much more potently than serotonin uptake [56].
9. Exclusions, repeated use, and limits of extrapolation
α-PVP’s own hazards. Analytically confirmed α-PVP poisonings in the Swedish STRIDA series involved tachycardia, agitation and hypertension. Additional detected substances included opioids, benzodiazepines and ethanol [57]. Among the 42 confirmed cases with no other stimulant detected, 7 were classified as severe (grade 3 on the Poisoning Severity Score, PSS) and 2 were fatal (PSS 4). α-PVP was the only psychoactive substance identified in 14 of 42 cases; the remaining cases involved other substances. These are findings from an α-PVP poisoning series, not outcomes established for DXM–α-PVP [57].
9. Exclusions, repeated use, and limits of extrapolation
A polysubstance α-PBP series lists α-PVP and dextromethorphan detections in an aggregate table. Their overlap and outcomes of a DXM–α-PVP pair remain unspecified in that table [58].
10. Reassessing historical FAQ claims
10. Reassessing historical FAQ claims · Historical claim or grouping / Current interpretation
| Historical claim or grouping | Current interpretation |
|---|---|
| MDMA, MDA, and 2C-B grouped as phenethylamines | Interaction mechanisms differ among substances within a chemical class. MDMA has direct pharmacokinetic interaction data. |
| Opioids treated as one class | Separate respiratory and serotonergic mechanisms |
| Ketamine largely displaces DXM effects because of a shared binding site | Inadequate explanation; quantitative interaction remains poorly studied |
| N2O potentiates DXM without additional adverse effects | Subjective potentiation is plausible; absence of physical hazard is not established |
| Ethanol or other agents protect against presumed NMDA-related neurotoxicity | No clinical basis to regard them as prevention of injury |
| Yohimbine produces Olney’s lesions with DXM | Such injury is not established in humans; assess autonomic stress instead |
| Cigarettes can be treated as nicotine or as a conventional MAOI | Nicotine and tobacco smoke differ. Reduced MAO activity has been described in smokers; prescribed MAOI exposure occurs under different conditions. |
| Sedating antihistamines are neutral additions | Consider chlorphenamine’s SERT effects, sedation, anticholinergic effects, and possible CYP inhibition |
| Good subjective tolerability establishes safety | It does not exclude hyperthermia, arrhythmias, aspiration, or altered exposure |
10. Reassessing historical FAQ claims
The Olney’s lesions hypothesis belongs to the historical discussion. The grounds for numerical ratings are given in the individual combination descriptions. Injury during severe intoxication is a broader question than this hypothesis.
11. Harm-reduction implications
11. Harm-reduction implications
DXM with traditional MAOIs has the strongest grounds for avoidance based on contraindications and clinical signals. MDMA shares the highest concern band by a different route: multiple interacting mechanisms and demonstrated PK amplification, with limited direct clinical outcome data. Tramadol and other combinations involving several toxicity pathways also warrant high concern. With overlapping PHI ranges, confidence in the evidence and outcome probabilities may differ. With depressants, experience and lack of anxiety do not substitute for adequate breathing and protective reflexes. A low index means only a lower expected physiological hazard under the stated assumptions.
11. Harm-reduction implications
DXM alone must be distinguished from combination medicines. Acetaminophen (paracetamol), chlorphenamine, sedating antihistamines, and sympathomimetic decongestants can create their own toxicity when more of the product is taken. These ingredients place the product outside most two-substance rows [6, 7, 25]. Extended-release formulations also alter the duration of overlapping effects.
11. Harm-reduction implications
If excessive acetaminophen or paracetamol intake is suspected, contact a poison centre or emergency department immediately, even if the person feels well. Early symptoms may be absent while liver injury develops later. Waiting for symptoms can delay effective treatment [37].
11. Harm-reduction implications
Seizures, slow or difficult breathing, inability to awaken the person, marked rigidity or repeated involuntary muscle contractions with escalating overheating, chest pain, or collapse require emergency assessment. They should not be dismissed as an intense trip or assumed manageable through psychological resilience.
11. Harm-reduction implications
In Canada, call 911 immediately if the person is unconscious, is not breathing, or is having a seizure. Do not wait for a poison-centre consultation [38].
11. Harm-reduction implications
For suspected poisoning without an immediate life-threatening emergency:
Canada, except Québec and Nunavut: 1-844-764-7669 (POISON-X), available around the clock and routed to the local poison centre.
Québec: 1-800-463-5060.
Nunavut: contact the local health centre or health unit; the listed specialist line is intended for healthcare professionals [47].
Elsewhere: contact the local poison centre; use the local emergency number for a life-threatening emergency.
11. Harm-reduction implications
Canadian contacts were checked against Health Canada and the Canadian Association for Poison Centres and Clinical Toxicology on 2 October 2026 [36, 47]. The brief warning-sign list helps identify reasons to seek emergency help [2, 12, 25, 36].
Persistent interactions after subjective effects have ended
Persistent interactions after subjective effects have ended
Interaction hazards are not limited to simultaneous intoxication. The MDMA study abstract reports CYP2D6 recovery after approximately 10 days; the full-text recovery modelling and its limitations are described in the study explanation [3]. In a fluoxetine study using DXM as a probe, CYP2D6 inhibition persisted for two weeks after fluoxetine was discontinued [50]. AUVELITY and NUEDEXTA labels specify MAOI separation requirements, including 14-day intervals in the relevant directions [2, 4]. Study times describe the endpoint studied; label intervals are tied to the product and direction of prescribing. Recovery depends on the drug, regimen, and person; prescribed medicines should not be stopped or rescheduled to accommodate recreational use without professional advice.
If the combination has already been taken
If the combination has already been taken
For a high-concern combination, suspected excessive intake, or uncertain product composition, contact a poison centre promptly even if there are no symptoms. Provide the product names, ingredients, amounts, timing, other medicines, and any symptoms so the exposure can be assessed [25, 37, 38]. Avoid further nonprescribed substances, driving, and hazardous activity while seeking advice; a sober person can help monitor changes and call for assistance. Symptoms may appear later, particularly with extended-release products, metabolic inhibition, or acetaminophen. Emergency signs take priority over poison-centre consultation.
Canadian legal protections when seeking emergency help
Canadian legal protections when seeking emergency help
For a qualifying life-threatening medical emergency induced by a psychoactive substance, the Good Samaritan Drug Overdose Act provides protection against simple-possession charges and certain possession-related breaches of conditions to people seeking emergency assistance during an overdose, including the person overdosing, and to others covered at the scene; protection is limited and does not cover outstanding warrants, trafficking, production, or unrelated offences [48]. In R. v. Wilson, 2025 SCC 32 (24 October 2025), the Supreme Court confirmed that the statutory immunity also precludes arrest for the protected simple-possession offence; this is not blanket immunity from police action for other offences [49].
12. References
12. References
[1] White WE. The Dextromethorphan FAQ. Text Version 4.0. 1997. Historical source; Section 13 and related warnings. Includes user reports.
12. References
[2] AUVELITY prescribing information. DailyMed. Prescribing information: serotonin toxicity, MAOIs, CYP2D6, and bupropion. Accessed 2 October 2026. Source
12. References
[3] O’Mathúna B et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 2008;28(5):523–529. DOI 10.1097/JCP.0b013e318184ff6e. Human pharmacokinetic study; abstract and selected full-text methods, results and discussion checked for this proposed revision. Bibliographic pages: 523–529; the publisher PDF is printed as 525–531. Source
12. References
[4] NUEDEXTA prescribing information. DailyMed. Prescribing information: metabolism, MAOIs, serotonin toxicity, and QT. Accessed 2 October 2026. Source
12. References
[5] Rickli A et al. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175:532–543. DOI 10.1111/bph.14105. In vitro transporter experiments and clinical reports. Source
12. References
[6] Monte AA, Chuang R, Bodmer M. Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review. Br J Clin Pharmacol. 2010;70:794–798. DOI 10.1111/j.1365-2125.2010.03747.x. Cases primarily involve overdose. Source
12. References
[7] Jung JK, Zazay I, Burmeister JR, Shaghaghi N. Serotonin syndrome induced by Bromfed DM in a patient on sertraline. SAGE Open Medical Case Reports. 2025. DOI 10.1177/2050313X251392069. Single case involving a multicomponent syrup. Source
12. References
[8] Halman A et al. Drug–drug interactions involving classic psychedelics: A systematic review. 2024. DOI 10.1177/02698811231211219. General interaction literature; not a DXM combination trial. Source
12. References
[9] Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010;11(8):659–666. DOI 10.2174/138920010794233495. Source
12. References
[10] Bansal S et al. Evaluation of Cytochrome P450 Mediated Cannabinoid Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023;114:693–703. DOI 10.1002/cpt.2973. Human CYP-probe study. Source
12. References
[11] Felmlee MA, Morse BL, Morris ME. γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. AAPS J. 2021;23(1):22. DOI 10.1208/s12248-020-00543-z. Source
12. References
[12] FDA. Gabapentin and Pregabalin Drug Safety Communication. Respiratory safety warning; not a DXM study. Source
12. References
[13] UK Advisory Council on the Misuse of Drugs. Nitrous oxide updated harms assessment. 2023. Hypoxia and B12-related harms; not a DXM study. Source
12. References
[14] NAMENDA prescribing information. DailyMed. Prescribing information notes insufficient assessment of NMDA-antagonist combinations. Accessed 2 October 2026. Source
12. References
[15] Suzuki J et al. Toxicities associated with NBOMe ingestion—a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2015. PMID 25659919. Source
12. References
[16] Moss MJ, Hendrickson RG. Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002–2016. Clin Toxicol (Phila). 2019;57(2):99–103. Published online 2018. DOI 10.1080/15563650.2018.1497169. Source
12. References
[17] Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011;115:150–155. Source
12. References
[18] Hamelin BA et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67(5):466–477. DOI 10.1067/mcp.2000.106464. Source
12. References
[19] Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15(4):263–269. DOI 10.1097/00004714-199508000-00005. Source
12. References
[20] Shiran MR et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2003. PMID 12895196. Source
12. References
[21] Grossman E et al. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993. PMID 7690091. Source
12. References
[22] Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 2002;71(10):1149–1160. DOI 10.1016/S0024-3205(02)01799-X. Source
12. References
[23] Cai WM, Chen B, Ling SS, Zhang YD. Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. Br J Clin Pharmacol. 2001;51(1):107–108. DOI 10.1046/j.1365-2125.2001.01322.x. Source
12. References
[24] Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics. 1993;3(4):197–204. DOI 10.1097/00008571-199308000-00004. Source
12. References
[25] American College of Medical Toxicology. Dextromethorphan FAQ. Educational material on poisoning and interactions. Source
12. References
[26] RASAGILINE prescribing information. DailyMed. DXM contraindication, including psychosis and unusual behavior warnings. Accessed 2 October 2026. Source
12. References
[27] Harada T et al. A fatal intoxication case due to the serotonin syndrome induced by dextromethorphan and moclobemide overdose. Leg Med (Tokyo). 2025;74:102604. DOI 10.1016/j.legalmed.2025.102604. Postmortem overdose report; not an estimate of outcome frequency. Source
12. References
[28] Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60(3):295–307. PMID 8841152. DOI 10.1016/S0009-9236(96)90056-9. PK comparison between phenotypes and the effect of quinidine. Source
12. References
[29] Tanna RS et al. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clin Pharmacol Ther. 2023;113:1315–1325. DOI 10.1002/cpt.2891. DXM as a probe after one low kratom exposure. Source
12. References
[30] ONDANSETRON prescribing information. DailyMed. QT effects and regulatory serotonin-syndrome warning. Accessed 2 October 2026. Source
12. References
[31] Rojas-Fernandez CH. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs Real World Outcomes. 2014;1:3–5. DOI 10.1007/s40801-014-0004-3. Source
12. References
[32] SCOPOLAMINE prescribing information. DailyMed. Anticholinergic effects, hyperthermia, and CNS interactions; extrapolation to DXM. Accessed 2 October 2026. Source
12. References
[33] PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE prescribing information. DailyMed. Sedation and other warnings for the therapeutic combination product. Accessed 2 October 2026. Source
12. References
[34] ZELAPAR selegiline prescribing information. DailyMed. DXM contraindication and limits of MAO-B selectivity. Accessed 2 October 2026. Source
12. References
[35] Khoshnam-Rad N et al. Datura poisoning in a family: Case series and literature review. Clin Case Rep. 2022. DOI 10.1002/ccr3.6091. Source
12. References
[36] Health Canada. Canada launches new toll-free 1-844 POISON-X number for poison centres. 2023. Canadian poison-centre numbers and availability. Source
12. References
[37] National Capital Poison Center. Use acetaminophen safely: Tips to prevent poisoning. Absence of early symptoms and prompt consultation for suspected overdose. Source
12. References
[38] National Capital Poison Center. First aid: Act fast! Immediate emergency response to collapse, seizures, impaired breathing, or inability to awaken. Source
12. References
[39] Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001;41(5):563–572. DOI 10.1177/00912700122010302. Source
12. References
[40] LINEZOLID prescribing information. DailyMed. Direct DXM interaction findings in healthy volunteers. Accessed 2 October 2026. Source
12. References
[41] Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007. DOI 10.1038/sj.bjp.0707430. Source
12. References
[42] Rivers N, Horner B. Possible lethal reaction between nardil and dextromethorphan. Can Med Assoc J. 1970;103(1):85. PMID 20311659. Source
12. References
[43] Härtter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology. 1998;135:22–26. DOI 10.1007/s002130050481. Source
12. References
[44] XADAGO (safinamide) prescribing information. DailyMed. DXM contraindication and psychiatric rationale. Accessed 2 October 2026. Source
12. References
[45] Aarnoutse RE et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78(6):664–674. DOI 10.1016/j.clpt.2005.09.001. Source
12. References
[46] Wyen C et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther. 2008. DOI 10.1038/sj.clpt.6100452. PMID 18183034. Source
12. References
[47] Canadian Association for Poison Centres and Clinical Toxicology. Poison-centre contacts and Nunavut public-access instructions. Accessed 2 October 2026. National contacts · Ontario centre and Nunavut instructions
12. References
[48] Health Canada. About the Good Samaritan Drug Overdose Act; Department of Justice Canada. Controlled Drugs and Substances Act, section 4.1. Accessed 2 October 2026. Official guidance · Statutory definition and protections
12. References
[49] Supreme Court of Canada. R. v. Wilson, 2025 SCC 32. 24 October 2025. Official case summary. Source
12. References
[50] Amchin J et al. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol. 2001;41(4):443–451. DOI 10.1177/00912700122010159. Source
12. References
[51] Tramadol hydrochloride tablets prescribing information. DailyMed. Prescribing information: 07/2024; Medication Guide: 10/2025. Accessed 16 October 2026. Source
12. References
[52] DEMEROL oral prescribing information. DailyMed. Prescribing information: 03/2021; oral tablets and solution. Accessed 16 October 2026. Source
12. References
[53] DOLOPHINE prescribing information. DailyMed. Prescribing information: 06/2021; Medication Guide: 12/2022. Accessed 16 October 2026. Source
12. References
[54] Codeine sulfate tablets prescribing information. Hikma Pharmaceuticals USA Inc. DailyMed. Revised 12/2025; updated 22 December 2025. Sections 5.2, 5.3, 5.6, 5.7, 12.3. Accessed 16 October 2026. Source
12. References
[55] Crews KR et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888–896. DOI 10.1002/cpt.2149. CPIC author PDF; pages 3–4, Codeine and Table 2. Source
12. References
[56] Kolaczynska KE, Thomann J, Hoener MC, Liechti ME. The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. Int J Mol Sci. 2021;22(15):8277. DOI 10.3390/ijms22158277. Human-transporter cell experiments. Source
12. References
[57] Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clin Toxicol (Phila). 2016;54(7):568–575. DOI 10.1080/15563650.2016.1190979. Abstract accessed 16 October 2026; full text not read. Source
12. References
[58] Franzén L, Bäckberg M, Beck O, Helander A. Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project. J Med Toxicol. 2018;14(4):265–271. DOI 10.1007/s13181-018-0668-2. Aggregate co-detection table; patient-level overlap of α-PVP and DXM unspecified. Source
12. References
The sources support the mechanisms and findings discussed; PHI ratings are the review’s unvalidated interpretive judgments.